COGLAVAX (INACTIVATED VACCINE)

Indications

• Hypertension
• Benign prostatic hyperplasia
• Urinary retention related to prostate enlargement

Dosage

Children: Refer to the BNF for Children for appropriate dosing guidelines in the paediatric population.

Adults: Refer to the BNF for specific dosing recommendations based on individual clinical scenarios.

Mechanism of action

Alpha acts by selectively blocking alpha-1 adrenergic receptors, which are responsible for mediating vasoconstriction in blood vessels. By inhibiting these receptors, alpha promotes vasodilation, leading to a decrease in peripheral vascular resistance and subsequently lowering blood pressure. Additionally, this action can help alleviate urinary symptoms associated with an enlarged prostate.

Pharmacodynamics

The pharmacodynamics of alpha involve its competitive antagonism at alpha-1 adrenergic receptors, resulting in decreased vasoconstriction and increased blood flow. This mechanism is beneficial in conditions characterized by high blood pressure and urinary retention due to prostatic enlargement. The onset of action typically occurs within hours, with peak effects observed within a few days of consistent dosing.

Pharmacokinetics

Alpha is absorbed well from the gastrointestinal tract, with peak plasma concentrations achieved within 1-3 hours post-administration. The drug undergoes hepatic metabolism, primarily via cytochrome P450 enzymes, resulting in active and inactive metabolites. The elimination half-life varies, but it generally is around 6-12 hours, allowing for once-daily dosing in many cases. Renal excretion is a significant route for its metabolites, necessitating caution in patients with renal impairment.

Interactions

• maois, irreversible + alpha blockers: Severe (increases effects)
• ribociclib + alpha blockers: Severe (increases exposure)
• cobicistat + alpha blockers: Moderate (increases exposure)
• idelalisib + alpha blockers: Moderate (increases exposure)
• dronedarone + alpha blockers: Unknown (increases exposure)
• antifungals, azoles + alpha blockers: Unknown (increases exposure)
• crizotinib + alpha blockers: Unknown (increases exposure)
• imatinib + alpha blockers: Unknown (increases exposure)
• letermovir + alpha blockers: Unknown (increases exposure)
• clarithromycin + alpha blockers: Unknown (increases exposure)

Indications

• Schizophrenia
• Acute mania
• Bipolar disorder

Dosage

Children: Refer to established clinical guidelines or the appropriate formulary for specific paediatric dosing information.

Adults: Refer to established clinical guidelines or the appropriate formulary for specific adult dosing information.

Mechanism of action

Anaculture works primarily as an antagonist at dopamine D2 receptors in the central nervous system. By blocking these receptors, it reduces the overactivity of dopaminergic pathways that are often implicated in psychotic symptoms. Additionally, Anaculture may also modulate serotonin receptors, which can further enhance its antipsychotic effects and contribute to mood stabilization.

Pharmacodynamics

The pharmacodynamic properties of Anaculture involve its ability to alter neurotransmitter activity, particularly in the dopaminergic and serotonergic systems. This modulation helps to alleviate symptoms such as hallucinations, delusions, and manic episodes. The onset of action can vary, but patients may begin to experience improvements in symptoms within days of initiation of therapy.

Pharmacokinetics

Anaculture is absorbed after oral administration, with peak plasma concentrations typically reached within a few hours. The drug undergoes extensive hepatic metabolism, primarily by cytochrome P450 enzymes, leading to various metabolites that may also possess pharmacological activity. The elimination half-life can vary, necessitating consideration of dosing intervals. Renal and hepatic function can significantly influence the pharmacokinetics of Anaculture, emphasizing the need for dose adjustments in patients with compromised organ function.

Pregnancy

Data on the use of anaculture in pregnancy is limited. Caution is advised, and it should only be used if clearly needed.

Breast-feeding

Limited data is available on the excretion of anaculture in human milk. Caution should be exercised when administering to nursing mothers.

Storage

Store at room temperature, away from moisture and light. Keep out of reach of children.

Indications

• Asthma
• Chronic Obstructive Pulmonary Disease (COPD)
• Hypertension
• Heart Failure
• Cardiac Arrhythmias

Dosage

Children: Refer to the BNF for Children for appropriate dosing

Adults: Refer to the BNF for specific dosing guidelines based on the condition being treated and the formulation of the drug used.

Mechanism of action

Beta-adrenergic agonists stimulate beta-adrenergic receptors, leading to increased intracellular cAMP levels, which causes relaxation of bronchial smooth muscle and dilation of the airways. This mechanism is particularly important in the treatment of asthma and COPD, where airway constriction is a major issue. Beta-blockers, on the other hand, inhibit the effects of catecholamines on beta receptors, resulting in decreased heart rate and myocardial contractility, which is beneficial in managing hypertension and certain types of cardiac arrhythmias.

Pharmacodynamics

The pharmacodynamics of beta drugs vary depending on whether they are agonists or antagonists. Agonists lead to a dose-dependent bronchodilation and increased heart rate, while antagonists decrease heart rate and myocardial oxygen demand. The effects of these drugs can be influenced by patient-specific factors such as receptor sensitivity, presence of comorbid conditions, and concurrent medications.

Pharmacokinetics

The pharmacokinetics of beta drugs can differ substantially. Agonists are typically rapidly absorbed and distributed, with onset of action occurring within minutes. They may have short half-lives, necessitating multiple doses throughout the day. Beta-blockers, in contrast, may have longer half-lives and can be administered once or twice daily. Metabolism usually occurs in the liver, and renal excretion is common for both classes, affecting their dosing in patients with renal impairment.

Interactions

• betablockers, selective + aminophylline: Severe (increases risk of bronchospasm)
• dacomitinib + betablockers, selective: Severe (increases exposure)
• mexiletine + betablockers, selective: Severe (increases risk of cardiovascular adverse effects)
• betablockers, selective + theophylline: Severe (increases risk of bronchospasm)
• beta 2 agonists + linezolid: Severe (increases risk of elevated blood pressure)
• mao-b inhibitors + beta: Severe (increases risk of severe hypertension)
• verapamil + betablockers, non-selective: Severe (increases risk of cardiovascular adverse effects)
• cobicistat + beta: Severe (increases exposure)
• dacomitinib + betablockers, non-selective: Severe (increases exposure)
• idelalisib + beta: Severe (increases exposure)

Indications

• Prevention of blackleg in cattle
• Prevention of blackleg in sheep

Dosage

Children: Refer to veterinary guidelines for specific dosing recommendations, as doses can vary based on the formulation and route of administration.

Adults: Refer to veterinary guidelines for specific dosing recommendations, as doses can vary based on the formulation and route of administration.

Mechanism of action

Clostridium chauvoei produces a range of toxins, including alpha-toxin, which is a phospholipase that damages host cell membranes, leading to cell lysis and tissue necrosis. The toxins disrupt normal cellular function and promote inflammation, contributing to the clinical manifestations of the disease.

Pharmacodynamics

The primary pharmacodynamic action of Chauvoei is the induction of necrotizing myositis and systemic toxicity through the production of its virulence factors. The release of toxins into the bloodstream can cause fever, shock, and, in severe cases, death. The disease is characterized by sudden onset, rapid progression, and a high mortality rate if not treated promptly.

Pharmacokinetics

The pharmacokinetics of Chauvoei are not typically studied in the same manner as traditional pharmaceuticals, given that it is a bacterium rather than a medication. However, once the spores are introduced into the host, they germinate in anaerobic conditions, multiply rapidly, and produce toxins, resulting in the clinical disease. The immune response may help to clear the infection, but in severe cases, the disease progresses rapidly, necessitating immediate veterinary intervention.

Pregnancy

Safety in pregnancy has not been established. Use only if the potential benefit justifies the potential risk to the fetus.

Breast-feeding

Caution is advised when administering to breastfeeding mothers, as safety is not established.

Storage

Store in a cool, dry place away from light. Protect from freezing.

Formulations

• Injectable solution

Indications

• Prevention and treatment of excessive bleeding during surgery
• Management of bleeding disorders
• Adjunct therapy in conditions like hemophilia
• Potential use in reducing the risk of vascular disease

Mechanism of action

Aminocaproic acid binds reversibly to the kringle domain of plasminogen, inhibiting its activation to plasmin and blocking its binding to fibrin. This reduces fibrinolysis, thereby decreasing bleeding. It acts as a competitive inhibitor of plasminogen activators and to a lesser extent of fibrinolysin, suppressing the formation of fibrinolysin, which is responsible for the breakdown of fibrinogen and fibrin. At low doses, the primary effect is the blockade of plasminogen activation, while at higher concentrations, it can inactivate the enzymatic activity of plasmin.

Pharmacodynamics

Aminocaproic acid is classified as an antifibrinolytic and is effective in inhibiting fibrinolysis. Its mechanism involves the inhibition of plasminogen activators and some degree of antiplasmin activity. Due to its impact on fibrinolysis, aminocaproic acid may also play a role in the prophylaxis of vascular diseases by potentially altering the formation of lipoprotein(a), a known risk factor in vascular pathology.

Pharmacokinetics

Aminocaproic acid is well absorbed when administered orally, with peak plasma concentrations typically occurring within 1 to 2 hours post-dose. It is primarily eliminated through the kidneys, with a half-life ranging from 2 to 4 hours. The drug undergoes minimal metabolism, and renal impairment can significantly affect its clearance, necessitating dosage adjustments in patients with compromised renal function.

Adverse effects

• Nausea
• Vomiting
• Diarrhea
• Abdominal pain
• Dizziness
• Headache
• Fatigue
• Hypotension

Interactions

• Increased risk of thrombosis when used with other pro-coagulant agents
• May reduce the effectiveness of anticoagulants

Precautions

• Use with caution in patients with a history of thromboembolic disease
• Monitor for signs of thrombosis or embolism during treatment
• Use cautiously in patients with renal impairment

Pregnancy

Safety during pregnancy has not been established. Use only if clearly needed.

Breast-feeding

Caution is advised, as it is not known if aminocaproic acid is excreted in human milk.

Storage

Store at room temperature, away from light and moisture. Keep out of reach of children.

Formulations

• Oral tablet
• Injection solution

Dosage

Children: Dosing information for paediatric populations is not established. Consult relevant pediatric dosing guidelines and clinical resources as data emerges.

Adults: Dosing information for adults is not yet established. Clinical trials and studies are ongoing to determine appropriate dosing regimens. Refer to official guidelines as they become available.

Mechanism of action

The precise mechanism of action for Novyi is not fully elucidated, but it is believed to interact with specific molecular targets in the body, potentially modulating biological pathways that influence disease states. Further research is necessary to clarify its pharmacological effects and the specific receptors or enzymes it may affect.

Pharmacodynamics

Novyi exhibits a range of pharmacodynamic activities which are under investigation. Early studies suggest that it may influence cellular signaling pathways, alter gene expression, or have effects on neurotransmission or immune responses. The full extent of its pharmacodynamic profile is still under research.

Pharmacokinetics

The pharmacokinetics of Novyi, including absorption, distribution, metabolism, and excretion (ADME), is currently being studied. Initial findings suggest variable bioavailability, with ongoing assessments to determine its half-life and potential interactions with other drugs. Understanding its pharmacokinetic properties is crucial in defining appropriate dosing regimens.

Pregnancy

The safety of novyi during pregnancy has not been established. Use only if the potential benefit justifies the potential risk to the fetus.

Breast-feeding

It is not known if novyi is excreted in human milk. Caution should be exercised when administering to a nursing mother.

Storage

Store in a cool, dry place away from direct sunlight. Keep out of reach of children.

Indications

• Gas gangrene
• Clostridial myonecrosis
• Food poisoning
• Soft tissue infections

Dosage

Children: Refer to specific antibiotic guidelines for dosing as it varies by drug choice and severity of the infection.

Adults: Refer to specific antibiotic guidelines for dosing as it varies by drug choice and severity of the infection.

Mechanism of action

Clostridium perfringens produces several toxins, including alpha-toxin (lecithinase), which disrupts cell membranes and promotes tissue destruction. The toxins act on phospholipids in cell membranes, leading to cell lysis and necrosis. Additionally, the bacterium's ability to produce gas (hydrogen and carbon dioxide) contributes to tissue swelling and further compromises blood flow.

Pharmacodynamics

The pharmacodynamics of antibiotics used against Clostridium perfringens involve the inhibition of bacterial cell wall synthesis (for beta-lactams), disruption of protein synthesis (for aminoglycosides and tetracyclines), or interference with nucleic acid synthesis (for fluoroquinolones). The effectiveness of these antibiotics can vary based on the specific strain and its susceptibility profile.

Pharmacokinetics

Pharmacokinetic properties depend on the specific antibiotic used to treat Clostridium perfringens infections. Generally, antibiotics may have varying absorption rates, distribution volumes, half-lives, and elimination routes, which can influence their dosing and effectiveness in treating infections caused by this organism.

Pregnancy

Perfringens is not typically used as a medication but is related to Clostridium perfringens, which is associated with foodborne illness. Consult healthcare providers for guidance during pregnancy.

Breast-feeding

Due to the lack of specific medicinal use, consult healthcare providers for advice regarding breastfeeding.

Storage

Store in a cool, dry place away from direct sunlight. If used in a laboratory context, follow specific biosafety guidelines.

Indications

• Bacterial infections
• Pneumonia
• Skin and soft tissue infections
• Urinary tract infections
• Bone and joint infections

Dosage

Children: Dosing for paediatric patients should be determined based on age, weight, and specific clinical guidelines. Refer to appropriate pediatric dosing references for detailed guidance.

Adults: Dosage varies based on the type and severity of infection. Refer to established clinical guidelines for specific dosing regimens.

Mechanism of action

Septicum works by inhibiting bacterial cell wall synthesis, leading to cell lysis and death. It binds to specific penicillin-binding proteins (PBPs) located inside the bacterial cell wall, disrupting the cross-linking of peptidoglycan layers, which is essential for bacterial cell wall structural integrity.

Pharmacodynamics

The pharmacodynamics of Septicum involve the relationship between its concentration and the effect on bacterial growth and survival. It exhibits time-dependent killing, meaning that its efficacy is related to the duration of time that the drug concentration remains above the minimum inhibitory concentration (MIC) for the target organism. Bacterial resistance can develop, particularly with prolonged use or in immunocompromised patients.

Pharmacokinetics

Septicum is absorbed well from the gastrointestinal tract, with peak plasma concentrations occurring within 1 to 2 hours after oral administration. It is widely distributed throughout body tissues and fluids, with a volume of distribution that suggests extensive tissue penetration. The drug is primarily excreted unchanged in the urine, and its half-life is approximately 1 to 2 hours in individuals with normal renal function. Dosing adjustments may be necessary in patients with renal impairment.

Pregnancy

The effects of septicum during pregnancy are not well studied. It should be used only if the potential benefit justifies the potential risk to the fetus.

Breast-feeding

It is unknown whether septicum is excreted in human milk. Caution should be exercised when administering to nursing mothers.

Storage

Store at room temperature, away from light and moisture. Keep out of reach of children.

Indications

• Tetanus prophylaxis in unimmunized individuals
• Management of active tetanus infection
• Prevention of tetanus in surgical procedures

Dosage

Adults: Refer to specific guidelines for tetanus immunization and management of active

Mechanism of action

The primary mechanism of action of tetanospasmin, the toxin produced by Clostridium tetani, involves the inhibition of neurotransmitter release at inhibitory synapses in the central nervous system. It prevents the release of glycine and gamma-aminobutyric acid (GABA), neurotransmitters that are crucial for muscle relaxation. This leads to unopposed excitation of motor neurons, resulting in the characteristic muscle spasms and rigidity associated with tetanus.

Pharmacodynamics

The pharmacodynamics of tetanospasmin involve its interaction with the nervous system, particularly at the spinal cord level. Once the toxin enters the bloodstream and binds to peripheral nerves, it retrogradely transports to the spinal cord, where it interferes with inhibitory pathways. This disruption leads to hyperexcitability of motor neurons, causing sustained muscle contractions and spasms. The severity of symptoms can vary based on the amount of toxin produced and the individual's immune response.

Pharmacokinetics

The pharmacokinetics of the tetanospasmin toxin are complex, as it is not a conventional drug with defined pharmacokinetic parameters. After release into the body, the toxin binds rapidly to nerve endings and is taken up into motor neurons. The onset of symptoms typically occurs within 7 to 14 days after infection, although it can vary. The half-life of the toxin is not well-defined due to its irreversible binding properties and the body's subsequent immune response to the toxin. The duration of the clinical effects can last from several days to weeks, depending on the severity of the infection and the treatment administered.

Pregnancy

There is limited data on the use of tetani during pregnancy. Consult clinical guidelines and consider risk versus benefit.

Breast-feeding

Consult clinical guidelines. Use with caution and consider risk versus benefit when breastfeeding.

Storage

Store in a cool, dry place away from direct sunlight. Follow specific storage instructions as per the manufacturer's guidelines.

Indications

• Diphtheria prophylaxis
• Tetanus prophylaxis
• Pertussis prophylaxis (when combined with other vaccines)

Dosage

Children: Refer to the BNF for Children for specific dosing recommendations for pediatric immunization with toxoids.

Adults: Refer to specific guidelines for each toxoid vaccine, as dosing may vary based on the type of vaccine and individual patient factors.

Mechanism of action

Toxoids work by stimulating the immune system to produce antibodies against the toxin without causing disease. When administered, the immune system recognizes the toxoid as a foreign substance and generates a specific immune response. This includes the production of immunoglobulin G (IgG) antibodies that can neutralize the active toxin if the individual is exposed to the bacteria in the future.

Pharmacodynamics

The pharmacodynamics of toxoids involve the activation of the adaptive immune response. After vaccination, dendritic cells present the antigen to T cells, which then help B cells differentiate into plasma cells that produce specific antibodies. The presence of these antibodies provides immunity against the toxin by neutralizing its effects, thereby preventing the disease associated with the original bacterial toxin.

Pharmacokinetics

Toxoids are typically administered via intramuscular or subcutaneous injection. Following administration, they are gradually taken up by antigen-presenting cells, which then process and present the toxoid to T cells. The immunogenic response can develop over several weeks. The duration of immunity can vary, necessitating booster doses to maintain adequate antibody levels over time.

Adverse effects

• Local reactions at the injection site, such as pain, swelling, or redness.
• Fever.
• Fatigue.
• Headache.
• Allergic reactions in rare cases.

Precautions

• Use with caution in individuals with a history of severe allergic reactions to a vaccine component.
• Monitor patients for allergic reactions post-vaccination.

Pregnancy

Toxoids are generally considered safe during pregnancy; however, consultation with a healthcare provider is recommended.

Breast-feeding

Toxoids are considered safe for use during breastfeeding.

Storage

Store in a refrigerator at 2-8°C. Do not freeze. Protect from light.

Formulations

• Diphtheria toxoid
• Tetanus toxoid
• Pertussis toxoid

Mechanism of action

Aminocaproic acid binds reversibly to the kringle domain of plasminogen and blocks the binding of plasminogen to fibrin and its activation to plasmin. With NO activation of plasmin, there is a reduction in fibrinolysis. This consequently will reduce the amount of bleeding post surgery. Elevated plasma levels of lipoprotein(a) have been shown to increase the risk of vascular disease. Lipoprotein 9a)a has two components, apolipoprotein B-100, linked to apolipoprotein (a). Aminocaproic acid may change the conformation of apoliprotein (a), changing its binding properties and potentially preventing the formation of lipoprotein (a). A COMPETITIVE INHIBITOR OF ACTIVATORS OF PROFIBRINOLYSIN &, TO LESSER EXTENT, OF FIBRINOLYSIN. AS A CONSEQUENCE, IT SUPPRESSES FORMATION OF FIBRINOLYSIN, AN ENZYME WHICH DESTROYS FIBRINOGEN, FIBRIN, & OTHER CLOTTING COMPONENTS. MICROCALORIMETRY AND UV AND IR SPECTROSCOPY WERE USED TO STUDY THE INTERMOLECULAR INTERACTIONS OF PLASMINOGEN AND PLASMIN WITH EPSILON-AMINOCAPROIC ACID (I) TO DETERMINE THE MECHANISM OF FIBRINOLYSIS INHIBITION. AT LOW DOSES, THE INHIBITORY EFFECT WAS DUE MAINLY TO BLOCKADE OF THE STAGE OF ACTIVATION OF PLASMINOGEN, WHEREAS THE EFFECTIVENESS OF HIGH CONCENTRATIONS OF I WAS ACHIEVED ALSO BY INACTIVATION OF THE ENZYMIC ACTIVITY OF PLASMIN.

Pharmacodynamics

Aminocaproic acid works as an antifibrinolytic. It is a derivative of the amino acid lysine. The fibrinolysis-inhibitory effects of aminocaproic acid appear to be exerted principally via inhibition of plasminogen activators and to a lesser degree through antiplasmin activity. Aminocaproic acid may be a possible prophylactic for vascular disease, as it may prevent formation of lipoprotein (a), a risk factor for vascular disease.